The primary purpose of this study is to find out if giving a 12 week course of Neulasta
(Pegylated granulocyte colony stimulating factor (GCSF)) to people with type 1 diabetes (T1D)
is safe. The secondary purpose of this research study is to determin if giving GCSF to
patients with T1D changes the immune system or preserves insulin production.
Phase:
Phase 1
Details
Lead Sponsor:
University of Florida
Collaborators:
Juvenile Diabetes Research Foundation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)